EPARs - Emtriva/Emtricitabine

EPARs for authorised medicinal products for human use - Emtriva

FICHA FARMACOLÓGICA de emtricitabine. Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. Febrero 2009.
Active Substance
Emtricitabine
International Nonproprietary Name or Common Name
Emtricitabine
Pharmaco-therapeutic Group
Nucleoside and nucleotide reverse transcriptase inhibitors
ATC Code
JO5AF09
Therapeutic Indication
Emtriva is indicated for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents.This indication is based on studies in treatment naïve patients and treatment experienced patients with stable virological control. There is no experience of the use of Emtriva in patients who are failing their current regimen or who have failed multiple regimens (see section 5.1).
When deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate.